Document Type
Article
Publication Date
2018
College/Unit
School of Medicine
Department/Program/Center
Medicine
Abstract
Ipilimumab is a monoclonal antibody that works as an immunotherapeutic agent through selective targeting of T cells to strengthen the response to metastatic melanoma. It is well known that this pharmaceutical agent can cause the adverse effect of colitis. We report a rare presentation of ileocolitis refractory to both glucocorticosteroids and infliximab with a resultant pneumatosis and perforation requiring subtotal colectomy and end ileostomy.
Digital Commons Citation
Poushanchi, Behdod; Vallabh, Hiren; and Reynolds, Gorman Joel, "A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab" (2018). Faculty & Staff Scholarship. 2094.
https://researchrepository.wvu.edu/faculty_publications/2094
Source Citation
Poushanchi, B., Vallabh, H., & Reynolds, G. J. (2018). A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab. Case Reports in Gastrointestinal Medicine, 2018, 1–3. https://doi.org/10.1155/2018/2431503
Comments
Copyright © 2018 Behdod Poushanchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.